H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1

H.C. Wainwright has maintained a Neutral rating and set a price target of $1.00 for Traws Pharma Inc. (NASDAQ:TRAW) following the company's second-quarter 2026 update. The firm anticipates resubmitting an updated toxicology package to the MHRA by the end of Q3 2026, with a formal response expected within 30 days. The U.S. clinical hold on the TXM drug candidate remains unresolved, and the planned Phase 2a challenge study has not been able to commence.

At the end of Q2 2026, Traws Pharma held $5.0 million in cash, relying partly on anticipated ATM proceeds to support operations through Q1 2027. Despite a 73% decline in stock price over the past six months and a 52% drop year-to-date, InvestingPro analysis suggests the stock is undervalued at current levels. The company's cash position surpasses its debt on the balance sheet, according to an InvestingPro tip.

H.C. Wainwright emphasizes the need for MHRA acceptance of the revised toxicology package and a viable capital path through the challenge study to restore investor confidence in TXM as a near-term value driver.